INTRODUCTION: Sacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slower than expected. Our objective was to develop a score predicting the super-response to SV in HF outpatients. METHODS: This is a retrospective analysis of 185 consecutive patients prescribed SV from two tertiary hospitals between September 2016 and February 2018. Super-responder was defined as a patient taking the drug and (i) without HF admissions, death, or heart transplant, and (ii) with a ≥50% reduction in NT-proBNP levels and/or an increase of ≥10 points in LVEF in a 12-month follow-up period after starting SV. Clinical, echocardiographic, ECG, and biochemical variables were used in a logistic regression analysis to construct a score for super-response to SV which was internally validated using bootstrap method. RESULTS: Out of 185 patients, 65 (35%) fulfilled the super-responder criteria. Predictors for super-response to SV were absence of both previous aldosterone antagonist and diuretic treatment, NYHA I-II class, female gender, previous 1-year HF admission, and sinus rhythm. An integrating score distinguished a low- (<25%), intermediate- (∼46%), and high-probability (>80%) for 1-year super-response to SV. The AUC for the model was 0.72 (95%CI: 0.64-0.80), remaining consistent after internal validation. CONCLUSION: One-third of our patients presented a super-response to SV. We propose an easy-to-calculate score to predict super-response to SV after 1-year initiation based on variables that are currently assessed in clinical practice.
INTRODUCTION: Sacubitril/valsartan (SV) promotes cardiac remodeling and improves prognosis in patients with heart failure (HF). However, the response to the drug may vary between patients and its implementation in daily clinical practice has been slower than expected. Our objective was to develop a score predicting the super-response to SV in HF outpatients. METHODS: This is a retrospective analysis of 185 consecutive patients prescribed SV from two tertiary hospitals between September 2016 and February 2018. Super-responder was defined as a patient taking the drug and (i) without HF admissions, death, or heart transplant, and (ii) with a ≥50% reduction in NT-proBNP levels and/or an increase of ≥10 points in LVEF in a 12-month follow-up period after starting SV. Clinical, echocardiographic, ECG, and biochemical variables were used in a logistic regression analysis to construct a score for super-response to SV which was internally validated using bootstrap method. RESULTS: Out of 185 patients, 65 (35%) fulfilled the super-responder criteria. Predictors for super-response to SV were absence of both previous aldosterone antagonist and diuretic treatment, NYHA I-II class, female gender, previous 1-year HF admission, and sinus rhythm. An integrating score distinguished a low- (<25%), intermediate- (∼46%), and high-probability (>80%) for 1-year super-response to SV. The AUC for the model was 0.72 (95%CI: 0.64-0.80), remaining consistent after internal validation. CONCLUSION: One-third of our patients presented a super-response to SV. We propose an easy-to-calculate score to predict super-response to SV after 1-year initiation based on variables that are currently assessed in clinical practice.
Authors: Pierpaolo Pellicori; Alessia Urbinati; Parin Shah; Alexandra MacNamara; Syed Kazmi; Riet Dierckx; Jufen Zhang; John G F Cleland; Andrew L Clark Journal: Eur J Heart Fail Date: 2017-02-27 Impact factor: 15.534
Authors: Michael R Zile; Brian L Claggett; Margaret F Prescott; John J V McMurray; Milton Packer; Jean L Rouleau; Karl Swedberg; Akshay S Desai; Jianjian Gong; Victor C Shi; Scott D Solomon Journal: J Am Coll Cardiol Date: 2016-12-06 Impact factor: 24.094
Authors: Eleni S Nakou; Maria E Marketou; Gregory I Chlouverakis; Alexandros P Patrianakos; Panos E Vardas; Fragiskos I Parthenakis Journal: Clin Cardiol Date: 2018-11-24 Impact factor: 2.882
Authors: John J V McMurray; Alice M Jackson; Carolyn S P Lam; Margaret M Redfield; Inder S Anand; Junbo Ge; Marty P Lefkowitz; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Adel R Rizkala; Shalini V Sabarwal; Amil M Shah; Sanjiv J Shah; Victor C Shi; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Maja Cikes; Eva Goncalvesova; Tzvetana Katova; Anamaria Kosztin; Malgorzata Lelonek; Nancy Sweitzer; Orly Vardeny; Brian Claggett; Pardeep S Jhund; Scott D Solomon Journal: Circulation Date: 2019-11-17 Impact factor: 29.690
Authors: Lourdes Vicent; Ana Ayesta; Alberto Esteban-Fernández; Manuel Gómez-Bueno; Javier De-Juan; Pablo Díez-Villanueva; Ángel Manuel Iniesta; Antonio Rojas-González; Ramón Bover-Freire; Diego Iglesias; Marcos García-Aguado; Jesús A Perea-Egido; Manuel Martínez-Sellés Journal: Cardiology Date: 2019-04-18 Impact factor: 1.869
Authors: Carlos G Santos-Gallego; Ariana P Vargas-Delgado; Juan Antonio Requena-Ibanez; Alvaro Garcia-Ropero; Donna Mancini; Sean Pinney; Frank Macaluso; Samantha Sartori; Merce Roque; Fernando Sabatel-Perez; Anderly Rodriguez-Cordero; M Urooj Zafar; Icilma Fergus; Farah Atallah-Lajam; Johanna P Contreras; Cathleen Varley; Pedro R Moreno; Vivian M Abascal; Anuradha Lala; Ronald Tamler; Javier Sanz; Valentin Fuster; Juan J Badimon Journal: J Am Coll Cardiol Date: 2020-11-13 Impact factor: 24.094
Authors: Pablo Díez-Villanueva; Lourdes Vicent; Francisco de la Cuerda; Alberto Esteban-Fernández; Manuel Gómez-Bueno; Javier de Juan-Bagudá; Ángel Manuel Iniesta; Ana Ayesta; Antonio Rojas-González; Ramón Bover-Freire; Diego Iglesias; Marcos García-Aguado; Jesús Ángel Perea-Egido; Jorge Salamanca; Manuel Martínez-Sellés Journal: Cardiology Date: 2020-01-15 Impact factor: 1.869